$300 Million Fund Launched for Growth Stage Startups in Healthtech Sector
In 2025, there were 81 venture capital, private equity, micro, and government-backed funds, marking a 40% increase in VC fund launches. HealthKois has launched a $300 million fund targeting growth-stage startups in the healthtech and life sciences sectors, managed by the HealthQuad leadership team. Since 2014, the sector has attracted over $7 billion in total funding.
HealthKois has announced the launch of a substantial new fund amounting to $300 million, aimed specifically at supporting growth stage startups within the healthtech and life sciences fields. This initiative is managed by the leadership team of HealthQuad, a company established in 2016.
Focus on Healthtech and Life Sciences
The newly launched fund is strategically positioned to bolster the healthtech sector, which has seen significant growth in recent years. Healthtech funding experienced a remarkable surge of 207% in 2024, increasing from $233 million to an impressive $716 million. This upward trend follows a peak in 2022 when funding reached $1.4 billion. Since 2014, total funding in this sector has surpassed $7 billion, underscoring its expanding footprint in the market.
HealthQuad's previous endeavor, HealthQuad Fund II, successfully closed at $162 million, demonstrating the firm’s capability and commitment to nurturing innovation in healthtech. The launch of this new fund is expected to continue this trajectory, providing vital capital to startups at a pivotal stage in their growth journey.
Trends in Venture Capital and Funding
The broader Indian startup ecosystem has been vibrant, with startups raising over $150 billion across approximately 10,500 deals. This ecosystem is supported by a robust venture capital landscape, which has seen an aggregate corpus of over $12.1 billion by December 2025. Notably, 58% of these funds are directed toward early-stage startups, highlighting a strong inclination towards nurturing nascent entrepreneurial efforts.
Despite the focus on early-stage ventures, there remains substantial interest in growth and late-stage startups, with 17 out of 77 funds catering to these stages. Various sectors have attracted investment, with fintech accounting for 16% of the new corpus, consumer-focused funds comprising 15.5%, and AI-centric vehicles representing 12% of the funding pool.
Investment Landscape and Key Players
ChrysCapital stands out as a significant player, having backed over 110 companies since its inception in 1999. Meanwhile, Trifecta Capital continues to make strategic investments across a diverse range of sectors, with a portfolio that includes companies such as ixigo, BlackBuck, and MobiKwik. This support extends to over 50 unicorns and soonicorns, reflecting the dynamic nature of the startup ecosystem.
In 2025, there were 81 venture capital, private equity, micro, and government-backed funds, marking a 40% increase in VC fund launches. This growth is indicative of the rising appetite for investing in innovative startups, as well as the maturation of the Indian venture capital market.
Global Context and Investor Considerations
The global venture capital landscape also plays a crucial role, with US venture funds actively investing in Israeli startups, known for their technological innovation. This cross-border investment dynamic highlights the global interest in nurturing technological advancements and the critical role of venture capital in facilitating startup growth.
For startups, securing funding from venture capitalists or angel investors can be pivotal. However, it is essential for entrepreneurs to understand investor goals and conduct due diligence before accepting investment. Post-investment, venture capitalists may influence business decisions, making it crucial for startups to align with investors who share their vision.
As HealthKois embarks on this new funding journey, it joins a global movement of capital deployment aimed at fostering innovation and growth in healthtech, ensuring that startups have the resources necessary to drive advancements in health and life sciences.